Lung Injury Prevention with Aspirin (LIPS-A)

A protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury

Daryl Jon Kor, Daniel S. Talmor, Valerie M. Banner-Goodspeed, Rickey E. Carter, Richard Hinds, Pauline K. Park, Ognjen Gajic, Michelle Ng Gong

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Introduction: Acute lung injury (ALI) is a devastating condition that places a heavy burden on public health resources. Although the need for effective ALI prevention strategies is increasingly recognised, no effective preventative strategies exist. The Lung Injury Prevention Study with Aspirin (LIPS-A) aims to test whether aspirin (ASA) could prevent and/or mitigate the development of ALI. Methods and analysis: LIPS-A is a multicentre, double-blind, randomised clinical trial testing the hypothesis that the early administration of ASA will result in a reduced incidence of ALI in adult patients at high risk. This investigation will enrol 400 study participants from 14 hospitals across the USA. Conditional logistic regression will be used to test the primary hypothesis that early ASA administration will decrease the incidence of ALI. Ethics and dissemination: Safety oversight will be under the direction of an independent Data and Safety Monitoring Board (DSMB). Approval of the protocol was obtained from the DSMB prior to enrolling the first study participant. Approval of both the protocol and informed consent documents were also obtained from the institutional review board of each participating institution prior to enrolling study participants at the respective site. In addition to providing important clinical and mechanistic information, this investigation will inform the scientific merit and feasibility of a phase III trial on ASA as an ALI prevention agent. The findings of this investigation, as well as associated ancillary studies, will be disseminated in the form of oral and abstract presentations at major national and international medical specialty meetings. The primary objective and other significant findings will also be presented in manuscript form. All final, published manuscripts resulting from this protocol will be submitted to Pub Med Central in accordance with the National Institute of Health Public Access Policy.

Original languageEnglish (US)
Article numbere001606
JournalBMJ Open
Volume2
Issue number5
DOIs
StatePublished - 2012

Fingerprint

Acute Lung Injury
Lung Injury
Aspirin
Randomized Controlled Trials
Clinical Trials Data Monitoring Committees
Manuscripts
Consent Forms
Health Resources
Research Ethics Committees
Incidence
National Institutes of Health (U.S.)
Public Policy
Health Policy
Ethics
Public Health
Logistic Models
Medicine
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lung Injury Prevention with Aspirin (LIPS-A) : A protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury. / Kor, Daryl Jon; Talmor, Daniel S.; Banner-Goodspeed, Valerie M.; Carter, Rickey E.; Hinds, Richard; Park, Pauline K.; Gajic, Ognjen; Gong, Michelle Ng.

In: BMJ Open, Vol. 2, No. 5, e001606, 2012.

Research output: Contribution to journalArticle

Kor, Daryl Jon ; Talmor, Daniel S. ; Banner-Goodspeed, Valerie M. ; Carter, Rickey E. ; Hinds, Richard ; Park, Pauline K. ; Gajic, Ognjen ; Gong, Michelle Ng. / Lung Injury Prevention with Aspirin (LIPS-A) : A protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury. In: BMJ Open. 2012 ; Vol. 2, No. 5.
@article{38324526365a4ecca38cf52b01d98cc3,
title = "Lung Injury Prevention with Aspirin (LIPS-A): A protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury",
abstract = "Introduction: Acute lung injury (ALI) is a devastating condition that places a heavy burden on public health resources. Although the need for effective ALI prevention strategies is increasingly recognised, no effective preventative strategies exist. The Lung Injury Prevention Study with Aspirin (LIPS-A) aims to test whether aspirin (ASA) could prevent and/or mitigate the development of ALI. Methods and analysis: LIPS-A is a multicentre, double-blind, randomised clinical trial testing the hypothesis that the early administration of ASA will result in a reduced incidence of ALI in adult patients at high risk. This investigation will enrol 400 study participants from 14 hospitals across the USA. Conditional logistic regression will be used to test the primary hypothesis that early ASA administration will decrease the incidence of ALI. Ethics and dissemination: Safety oversight will be under the direction of an independent Data and Safety Monitoring Board (DSMB). Approval of the protocol was obtained from the DSMB prior to enrolling the first study participant. Approval of both the protocol and informed consent documents were also obtained from the institutional review board of each participating institution prior to enrolling study participants at the respective site. In addition to providing important clinical and mechanistic information, this investigation will inform the scientific merit and feasibility of a phase III trial on ASA as an ALI prevention agent. The findings of this investigation, as well as associated ancillary studies, will be disseminated in the form of oral and abstract presentations at major national and international medical specialty meetings. The primary objective and other significant findings will also be presented in manuscript form. All final, published manuscripts resulting from this protocol will be submitted to Pub Med Central in accordance with the National Institute of Health Public Access Policy.",
author = "Kor, {Daryl Jon} and Talmor, {Daniel S.} and Banner-Goodspeed, {Valerie M.} and Carter, {Rickey E.} and Richard Hinds and Park, {Pauline K.} and Ognjen Gajic and Gong, {Michelle Ng}",
year = "2012",
doi = "10.1136/bmjopen-2012-001606",
language = "English (US)",
volume = "2",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Lung Injury Prevention with Aspirin (LIPS-A)

T2 - A protocol for a multicentre randomised clinical trial in medical patients at high risk of acute lung injury

AU - Kor, Daryl Jon

AU - Talmor, Daniel S.

AU - Banner-Goodspeed, Valerie M.

AU - Carter, Rickey E.

AU - Hinds, Richard

AU - Park, Pauline K.

AU - Gajic, Ognjen

AU - Gong, Michelle Ng

PY - 2012

Y1 - 2012

N2 - Introduction: Acute lung injury (ALI) is a devastating condition that places a heavy burden on public health resources. Although the need for effective ALI prevention strategies is increasingly recognised, no effective preventative strategies exist. The Lung Injury Prevention Study with Aspirin (LIPS-A) aims to test whether aspirin (ASA) could prevent and/or mitigate the development of ALI. Methods and analysis: LIPS-A is a multicentre, double-blind, randomised clinical trial testing the hypothesis that the early administration of ASA will result in a reduced incidence of ALI in adult patients at high risk. This investigation will enrol 400 study participants from 14 hospitals across the USA. Conditional logistic regression will be used to test the primary hypothesis that early ASA administration will decrease the incidence of ALI. Ethics and dissemination: Safety oversight will be under the direction of an independent Data and Safety Monitoring Board (DSMB). Approval of the protocol was obtained from the DSMB prior to enrolling the first study participant. Approval of both the protocol and informed consent documents were also obtained from the institutional review board of each participating institution prior to enrolling study participants at the respective site. In addition to providing important clinical and mechanistic information, this investigation will inform the scientific merit and feasibility of a phase III trial on ASA as an ALI prevention agent. The findings of this investigation, as well as associated ancillary studies, will be disseminated in the form of oral and abstract presentations at major national and international medical specialty meetings. The primary objective and other significant findings will also be presented in manuscript form. All final, published manuscripts resulting from this protocol will be submitted to Pub Med Central in accordance with the National Institute of Health Public Access Policy.

AB - Introduction: Acute lung injury (ALI) is a devastating condition that places a heavy burden on public health resources. Although the need for effective ALI prevention strategies is increasingly recognised, no effective preventative strategies exist. The Lung Injury Prevention Study with Aspirin (LIPS-A) aims to test whether aspirin (ASA) could prevent and/or mitigate the development of ALI. Methods and analysis: LIPS-A is a multicentre, double-blind, randomised clinical trial testing the hypothesis that the early administration of ASA will result in a reduced incidence of ALI in adult patients at high risk. This investigation will enrol 400 study participants from 14 hospitals across the USA. Conditional logistic regression will be used to test the primary hypothesis that early ASA administration will decrease the incidence of ALI. Ethics and dissemination: Safety oversight will be under the direction of an independent Data and Safety Monitoring Board (DSMB). Approval of the protocol was obtained from the DSMB prior to enrolling the first study participant. Approval of both the protocol and informed consent documents were also obtained from the institutional review board of each participating institution prior to enrolling study participants at the respective site. In addition to providing important clinical and mechanistic information, this investigation will inform the scientific merit and feasibility of a phase III trial on ASA as an ALI prevention agent. The findings of this investigation, as well as associated ancillary studies, will be disseminated in the form of oral and abstract presentations at major national and international medical specialty meetings. The primary objective and other significant findings will also be presented in manuscript form. All final, published manuscripts resulting from this protocol will be submitted to Pub Med Central in accordance with the National Institute of Health Public Access Policy.

UR - http://www.scopus.com/inward/record.url?scp=84866367331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866367331&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2012-001606

DO - 10.1136/bmjopen-2012-001606

M3 - Article

VL - 2

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 5

M1 - e001606

ER -